- MindBio (CSE:MBIO) has developed the world’s first AI prediction tool for drugs and alcohol intoxication using voice analysis
- MindBio Therapeutics is a Vancouver-based biotechnology company creating health prediction technologies using AI and machine learning
- MindBio stock has given back 82.50 per cent year-over-year
MindBio Therapeutics (CSE:MBIO), a clinical-stage biotechnology company, has developed the world’s first AI prediction tool for drugs and alcohol intoxication using voice analysis.
The tool uses proprietary AI models and more than 50 million data points based on years of drug and alcohol clinical trials, allowing it to make medically meaningful predictions.
The company’s innovation positions it to take a concerted step into the multi-billion-dollar global digital health diagnostics market, leveraging its technology across consumer and enterprise settings including the mining, healthcare, law enforcement, aviation and construction sectors.
Justin Hanka, MindBio’s chief executive officer, summed up the milestone in Tuesday’s news release, noting that “the digital health diagnostics market represents a significant opportunity for MindBio to leverage its diagnostics technology with a first-mover advantage in speech analytics for drugs and alcohol intoxication detection.”
MindBio is currently on a US road show to showcase the technology and plans to expand its reach into other difficult-to-detect drugs over time.
About MindBio Therapeutics
MindBio Therapeutics is a Vancouver-based biotechnology company creating health prediction technologies using AI and machine learning.
MindBio stock (CSE:MBIO) is down by 2.78 per cent trading at C$1.75 as of 9:43 am ET. The stock has given back 82.50 per cent year-over-year.
Join the discussion: Find out what investors are saying about this biotech stock on the MindBio Therapeutics Corp. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
For full disclaimer information, please click here.
